{
    "clinical_study": {
        "@rank": "68634", 
        "acronym": "ADAP", 
        "arm_group": [
            {
                "arm_group_label": "Adalimumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Every second week, mg: 160-80-40-40-40-40 12 weeks in all"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Given as the active comparator, every second week"
            }
        ], 
        "brief_summary": {
            "textblock": "This study wants to investigate the efficiency of biological treatment for chronic\n      pouchitis. Chronic pouchitis is inflammation in a reconstruction after removal of the colon,\n      a pouch. It is examined in patients with ulcerative colitis.\n\n      The primary objective evaluation is to evaluate the clinically effect of biological therapy\n      (adalimumab) in patients with chronic pouchitis.\n\n      Secondary objective is to evaluate the effect of biological therapy on the endoscopical and\n      histological inflammatory activity.\n\n      It is a double-blinded randomized placebo controlled study."
        }, 
        "brief_title": "Adalimumab in the Treatment of Chronic Pouchitis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ulcerative Colitis", 
            "Pouchitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer", 
                "Pouchitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Operated with proctocolectomy and construction of an IPAA\n\n          -  Prior to surgery diagnosed with ulcerative colitis according to established\n             clinically, radiologic, endoscopic and histological criteria.\n\n          -  Diagnosed with chronic pouchitis as defined above\n\n          -  PDAI \u2265 7, with the clinically part of PDAI >2 and the endoscopic part of PDAI >3\n\n          -  Age >18 years\n\n          -  Negative stool cultures for bacterial bowel pathogens and negative stool microscopy\n             for parasites\n\n          -  Serology negative for chronic hepatitis B\n\n          -  Negative examination for tuberculosis (including x-ray of thorax and a interferon\n             gamma test)\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Treatment with glucocorticoids within the last 4 weeks\n\n          -  Diagnosed with Crohn's disease\n\n          -  Need of an interpreter or if patients do not understand oral or written information.\n\n          -  Surgical complications as anal stenosis, leak of the anastomosis, or fistula arising\n             from the pouch\n\n          -  Abuse of medicine, alcohol or drugs\n\n          -  Ongoing treatment with NSAID (non steroid anti inflammatory drug)\n\n          -  Pregnancy or nursing\n\n          -  A diverting stoma\n\n          -  Malignancy or other severe chronic disease or expected longevity less than one year\n\n          -  Patients diagnosed with immune deficiency\n\n          -  Ongoing infectious disease\n\n          -  Contraindications against treatment with tumor necrosis factor-alpha antibody, such\n             as heart disease, former cancer disease, in vivo vaccination within the last 4 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670240", 
            "org_study_id": "2011-004268-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "Adalimumab", 
                "intervention_name": "Adalimumab", 
                "intervention_type": "Drug", 
                "other_name": "Humira"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "IPAA", 
            "Pouchitis", 
            "Ulcerative colitis", 
            "Pouch", 
            "Adalimumab", 
            "Humira"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "mie.kjaer@rsyd.dk", 
                "last_name": "Mie Dilling Kjaer, MD", 
                "phone": "+ 45 29913103"
            }, 
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "zip": "5000"
                }, 
                "name": "Odense University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Jens Kjeldsen, phd", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Mie Dilling Kjaer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Niels Qvist, Dr.med, professor", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Adalimumab (Humira) in the Treatment of Chronic Pouchitis", 
        "overall_contact": {
            "email": "mie.kjaer@rsyd.dk", 
            "last_name": "Mie Dilling Kjaer, MD", 
            "phone": "+ 45 29913103"
        }, 
        "overall_contact_backup": {
            "email": "jens.kjeldsen@rsyd.dk", 
            "last_name": "Jens Kjeldsen, Ph.d", 
            "phone": "+45 65412765"
        }, 
        "overall_official": {
            "affiliation": "Odense University Hospital", 
            "last_name": "Jens Kjeldsen, Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of patients with chronic  pouchitis achieving a clinical improvement, defined as a reduction in clinically PDAI \u2265 2 at any time within the 12 weeks of treatment with adalimumab (Humira).\nClinical PDAI (0-6 points)(pouchitis disease activity index)refers to fewer (0-1 point), number of bowel movements(0-2 points), rectal bleeding(0-1 point) and fecal urgency(0-2 points).", 
            "measure": "Clinical response on treatment with Adalimumab", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670240"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "Mie Dilling Kjaer", 
            "investigator_title": "Principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of patients with a clinical improvement (PDAI reduction \u2265 2)at week 12 See the description of clinical improvement and PDAI under primary endpoint", 
                "measure": "Clinical improvement after 12 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "The number of patients with pouchitis in remission at week 12 (total PDAI \u22644)", 
                "measure": "Clinical remission after 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Effect (reduction in PDAI)of adalimumab (Humira) on the endoscopical and histological activity in chronic pouchitis Endoscopical and histological activity is defined from PDAI (pouchitis disease activity index). Endoscopically the presence of Edema, Granularity, Friability, Loss of vascular pattern, Mucous exudates or Ulceration, gives 1 point each (max 6 points). Histological the presence of polymorphic nuclear leukocyte infiltration and ulceration each gives 1-3 points regarding severity (max 6 points)", 
                "measure": "Endoscopic and histologic response after treatment with Adalimumab", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Odense University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Southern Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hvidovre University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Aarhus University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "AbbVie", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Odense University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}